Pantop%2520d

# Pantop%2520d ## Overview Pantop%2520d is likely a typo or truncated entry. It may refer to **pantoprazole** (a proton pump inhibitor) or **pantoprazole + domperidone** (a combination used in some regions). For safety, this response assumes **pantoprazole** 20 mg and 40 mg tablets/IV. ## Primary Indications - Gastroesophageal reflux disease (GERD) - Erosive esophagitis - Zollinger-Ellison syndrome (hypersecretory conditions) - *H. pylori* eradication (part of combination therapy) - Stress ulcer prophylaxis (ICU setting) ## Adult Dosing - **GERD/esophagitis**: 40 mg PO daily; max 40 mg/day for 8 weeks. - **Maintenance of esophagitis**: 20 mg PO daily. - **Zollinger-Ellison**: Start 40 mg PO twice daily; titrate up to 240 mg/day (divided doses) based on acid output. - **Stress ulcer prophylaxis**: 40 mg IV once daily or 40 mg IV every 12 hours per local protocol. - **IV administration**: 40 mg over 15 minutes. ## Pediatric Dosing - **Children ≥5 years**: 15–20 kg: 20 mg PO daily; >20 kg: 40 mg PO daily for up to 8 weeks (GERD/esophagitis). - **Children <5 years**: Not established; use per local pediatric protocols. - **IV use**: Not routinely established for pediatrics; consult specialist. ## Dose Adjustments - **Hepatic impairment**: Severe (Child-Pugh C): max 20 mg/day (PO or IV). - **Renal impairment**: No adjustment needed, but long-term use not studied. - **Elderly**: No dose change; monitor for side effects. ## Contraindications - Hypersensitivity to pantoprazole or substituted benzimidazoles. - **Caution**: Concomitant use with atazanavir or rilpivirine (reduced antiretroviral absorption). ## Adverse Effects - Common: Headache, diarrhea, nausea, abdominal pain. - Serious (rare): *Clostridioides difficile* infection, acute interstitial nephritis, hypomagnesemia, vitamin B12 deficiency (long-term), bone fracture risk with high-dose or >1 year use. - IV: Phlebitis, injection site reaction. ## Key Drug Interactions - **Antiretroviral agents**: Atazanavir, rilpivirine, nelfinavir—reduced absorption; avoid. - **Methotrexate**: Increased methotrexate levels when used with high-dose MTX; separate doses. - **Warfarin**: Risk of increased INR; monitor. - **Citalopram**: Max dose 20 mg/day due to QT prolongation risk. - **CYP2C19 substrates**: Diazepam, phenytoin—may increase levels. ## Monitoring - **Baseline**: Assess indication, renal/hepatic function, electrolyte levels (Mg, Ca, K). - **Long-term**: Monitor for hypomagnesemia (especially with diuretics), B12 deficiency, bone density (if >1 year use). - **Therapeutic response**: Symptom relief (e.g., heartburn, regurgitation). - **IV therapy**: Infusion site, electrolytes. ## Clinical Pearls - Pantoprazole is a PPI; best taken 30–60 minutes before a meal (preferably breakfast). - **IV formulation** is ~70% bioequivalent to oral; switch to oral when patient can take PO. - **Sudden discontinuation** after long-term use may cause rebound acid hypersecretion; taper if used >8 weeks. - **Crushing tablets**: May be dispersed in water; do not crush delayed-release tablets; use oral suspension or granules if available. - **Cost**: Generic pantoprazole is widely available, but combination Pantop%2520d may not be interchangeable. **Disclaimer**: This information is for educational purposes. Dosing, indications, and safety profiles may vary by region and local protocol. Always verify with the current prescribing information and consult a clinical pharmacist or physician for individual patient needs.